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We compared the mechanistic and kinetic properties
of murine leukemia virus (MuLV) and human immuno-
deficiency virus type 1 (HIV-1) reverse transcriptases
(RTs) during RNA-dependent DNA polymerization and
mutation synthesis using pre-steady-state kinetic anal-
ysis. First, MuLV RT showed 6.5–121.6-fold lower bind-
ing affinity (Kd) to deoxynucleotide triphosphate
(dNTP) substrates than HIV-1 RT, although the two RTs
have similar incorporation rates (kpol). Second, com-
pared with HIV-1 RT, MuLV RT showed dramatic reduc-
tion during multiple dNTP incorporations at low dNTP
concentrations. Presumably, due to its low dNTP bind-
ing affinity, the dNTP binding step becomes rate-limit-
ing in the multiple rounds of the dNTP incorporation by
MuLVRT, especially at low dNTP concentrations. Third,
similar fold differences betweenMuLV and HIV-1 RTs in
the Kd and kpol values to correct and incorrect dNTPs
were observed. This indicates that these two RT pro-
teins have similar misinsertion fidelities. Fourth, these
two RT proteins have different mechanistic capabilities
regarding mismatch extension. MuLV RT has a 3.1-fold
lowermismatch extension fidelity, comparedwith HIV-1
RT. Finally, MuLV RT has a 3.8-fold lower binding affin-
ity to mismatched template/primer (T/P) substrate com-
pared with HIV-1 RT. Our data suggest that the active
site of MuLV RT has an intrinsically low dNTP binding
affinity, compared with HIV-1 RT. In addition, instead of
the misinsertion step, the mismatch extension step,
which varies between MuLV and HIV-1 RTs, contri-
butes to their fidelity differences. The implications
of these kinetic differences between MuLV and HIV-1
RTs on viral cell type specificity and mutagenesis are
discussed.
Retroviruses encode a versatile DNA polymerase called re-
verse transcriptase (RT).1 The function of RT is to synthesize
linear double-stranded proviral DNAs from single-stranded
positive sense viral RNA genomes during viral replication. In
order to catalyze this process, RTs perform several distinct
enzymatic reactions including RNA-dependent DNA polymeri-
zation, DNA-dependent DNA polymerization, strand transfer,
and RNase H cleavage (1). The DNA polymerase activity of RTs
has been targeted, using various types of RT inhibitors such as
nucleoside substrate-like compounds (i.e. azidothymidine
(AZT) and didanosine (ddI)) (2), as a means to reduce viral
replication in infected individuals. Lentiviruses such as human
immunodeficiency virus type 1 (HIV-1) uniquely infect termi-
nally differentiated/nondividing cells (i.e.macrophages) as well
as dividing cells (i.e. activated CD4 T cells), whereas oncore-
troviruses such as murine leukemia virus (MuLV) productively
replicate mainly in dividing cells (3, 4). Numerous studies have
reported that actively dividing cells have higher cellular de-
oxynucleotide triphosphate (dNTP) concentrations than nondi-
viding cells (5). Recently, it was reported that the cellular
dNTP concentration of human macrophages (40 nM) is 100
times lower than that of dividing CD4  T cells (5 M) (6).
Therefore, RTs from these two major groups of animal retrovi-
ruses may execute proviral DNA synthesis at very different
cellular dNTP availability.
RT of MuLV is the most extensively studied oncoretroviral
RT. Kinetic and structural features of MuLV RT have been
compared with those of HIV-1 RT, which is the most charac-
terized lentiviral RT. These two RTs share many similarities in
their enzymatic and molecular characteristics. Mutational
analyses of conserved amino acid residues between these two
RTs also demonstrate their functional resemblances. Interest-
ingly, however, several key enzymatic differences exist be-
tween these two RTs. Firstly, we and others have reported that
MuLV RT has higher steady-state Km values to natural dNTPs
than HIV-1 RT, although this difference varies, depending on
the types of substrates and assays used (6–11). This suggests
that HIV-1 RT efficiently incorporates dNTPs even at low
dNTP concentrations, compared with MuLV RT. We recently
postulated that the Km difference between these two RTs may
be related to the large cellular dNTP concentration difference
observed between cell types that lentiviruses and oncoretrovi-
ruses specifically infect (6). It is possible that the low Km value
of HIV-1 RT enables HIV-1 to efficiently synthesize proviral
DNA even in macrophages containing very low cellular dNTP
concentrations. Like HIV-1 RT, simian immunodeficiency virus
(SIV) RT also displays low fidelity and relatively low Km values
(12). However, mechanisms involved in these Km differences
remain to be explored.
Secondly, the M13 lacZ mutation assay demonstrated that
MuLV RT has a 15-fold higher fidelity than HIV-1 RT (13).
Various steady-state kinetic analyses also demonstrated that
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MuLV RT is more faithful than HIV-1 RT (13–15). Both MuLV
and HIV-1 RT proteins lack the 3 to 5 proofreading exonucle-
ase activity that many high fidelity host replication DNA poly-
merases (i.e. Pol) possess. Consequently, the fidelity differ-
ences between these two RTs are independent of the 3 to 5
exonuclease activity. A similar fidelity difference was also ob-
served between several oncoretroviral (avian myeloblastosis
virus RT (13, 16) and bovine leukemia virus RT (17, 18)) and
lentiviral RTs (simian immunodeficiency virus RT (12) and
equine infectious anemia virus RT (19)), supporting the gener-
alization that oncoretroviral RTs have higher fidelities than
lentiviral RTs. These two RTs (MuLV and HIV-1) showed sig-
nificant differences in mismatch extension fidelity rather than
misinsertion fidelity (20). As recently reported, it is becoming
increasingly apparent that the fidelity of HIV-1 RT contributes
to viral genomic mutagenesis. The primary source of HIV-1
mutagenesis is its RT rather than the host RNA polymerase II
that produces the viral genomes (21). Furthermore, we and
others have demonstrated that HIV-1 variants harboring high
fidelity mutant RTs produce reduced genomic mutation during
a single round of viral replication, compared with wild-type
virus (21, 22). In addition, human T-cell leukemia virus type I
(oncoretrovirus) generates less genomic mutation than HIV-1
during a single round of replication (23).
Thirdly, although the palm and fingers subdomains of these
two RTs are structurally very similar, unlike MuLV RT, HIV-1
RT works as a dimer (24, 25). Studies have shown that some
equivalent structural residues have different functional roles
in HIV-1 and MuLV RTs. When a Phe is substituted for the
Tyr183 residue in HIV-1 RT, the activity of the resulting mutant
enzyme is greatly reduced (26), but the equivalent mutation in
MuLV RT (Y222F) does not significantly alter the catalytic
activity of the polymerase (27). Finally, these two RTs show
different sensitivity to the nucleotide analog, 3TCTP. Whereas
wild-type HIV-1 RT is characteristically able to incorporate
this chain-terminating substrate, MuLV RT is much less sen-
sitive to this unnatural nucleotide analog (28–30). This differ-
ence results from variation in a single amino acid in the con-
served YXDD region found in their active sites (YMDD of
HIV-1 RT and YVDD of MuLV RT). Consistently, the Val and
Ile mutations at the Met184 residue of the HIV-1 YMDD se-
quence are selected during the 3TC treatment (31, 32). In
addition, these two 3TC-resistant HIV-1 RT mutants, M184V
and M184I, also show increased enzyme fidelity (33–35). These
findings suggest that the conserved YXDD region of RTs ap-
pears to be important to both 3TCTP selection and enzyme
fidelity. Therefore, MuLV and HIV-1 RTs, which are very sim-
ilar in general, appear to have different local structures and
unique enzymatic characteristics.
With the advent of rapid quench techniques, pre-steady-
state kinetic assays have been employed to study mechanistic
properties of DNA polymerases including RTs. These assays
can measure kinetic parameters associated with: 1) polymerase
binding to the T/P (KD), 2) subsequent binding of a dNTP
substrate (Kd), and 3) chemical incorporation of the nucleotide
onto the primer strand (kpol) (36, 37). Because mutation syn-
thesis is comprised of two mechanistically distinct DNA poly-
merization events, nucleotide misinsertion (i.e. misincorpora-
tion) and mismatch extension, we can evaluate the capability of
a polymerase to carry out these events by measuring the ki-
netics for nucleotide incorporation onto both matched and mis-
matched T/P. These types of studies have shown that HIV-1 RT
is relatively efficient at completing both these steps of misin-
corporation and mismatch extension (38–41). It was also re-
ported that HIV-1 RT distinguishes correct and incorrect
dNTPs at both the dNTP binding step (Kd) and the incorpora-
tion step (kpol), unlike the Klenow fragment of Escherichia coli
DNA polymerase I that predominantly uses the kpol step to
distinguish between correct and incorrect dNTPs (42).
To further expound upon the foundation laid by the afore-
mentioned studies demonstrating both the similarities and
differences between MuLV and HIV-1 RTs, we compared the
kinetic mechanisms involved in DNA polymerization and mu-
tation synthesis of MuLV and HIV-1 RTs using pre-steady-
state kinetic assays. Here, we compared the kinetic parameters
associated with dNTP incorporation, misincorporation and
mismatch extension, and T/P binding by MuLV and HIV-1 RTs.
Our study reveals that MuLV RT has a much lower binding
affinity to both correct and incorrect dNTPs than HIV-1 RT.
Overall, the study confirms that the higher fidelity of the
MuLV RT is likely due to its reduced ability to complete mis-
match extension (20). The implication of these mechanistic
discrepancies between MuLV and HIV-1 RTs on viral pheno-
typic differences is discussed.
EXPERIMENTAL PROCEDURES
Purification of MuLV RT—MuLV RT was overexpressed in E. coli
BL21 (Novagen) from the pMULVRT plasmid (43). The pMULVRT ex-
pression construct encodes for full-length MuLV RT fused at the N ter-
minus to six histidine residues. The hexahistidine-tagged RTwas purified
using Ni2 chelation chromatography as described previously (43–45).
From 1 liter of culture, we were able to purify 4 mg of monomeric MuLV
RT. Expression and purification of HIV-1 RT were described previously
(44). To examine the purity of the purified RT proteins, 4 g of the purified
RTs were analyzed in 10% SDS-polyacrylamide gels using 4 g of 98%
pure bovine serum albumin (Sigma-Aldrich) as a control. The gels visu-
alized by Coomassie Blue staining were analyzed by a densitometer, and
the purified RT proteins showed similar levels of minor contaminants to
the bovine serum albumin control, suggesting that the RT proteins used
in this study must have at least 95% purity.
Pre-steady-state Kinetic Assays—Pre-steady-state burst and single
turnover experiments were performed to examine the transient kinetics
associated with incorporating a single nucleotide onto either a matched
or mismatched T/P (39). To study the incorporation of each of the four
dNTPs (correct), four different 32P-labeled 23-mer primers (matched; A
primer, 5-CGCGCCGAATTCCCGCTAGCAAT-3; T primer, 5-CC-
GAATTCCCGCTAGCAATATTC-3; G primer, 5-CGAATTCCCGC-
TAGCAATATTCT-3; C primer, 5-GCCGAATTCCCGCTAGCAATA-
TT-3) were individually annealed to a 38-mer RNA template (5-
GCUUGGCUGCAGAAUAUUGCUAGCGGGAAUUCGGCGCG-3).
Reactions were performed using a Kintek Rapid Quench machine (37,
40, 46). Products were analyzed by 14% denaturing sequencing gel
electrophoresis and quantified with the Cyclone phosphorimager
(PerkinElmer Life Sciences). Pre-steady-state burst experiments were
employed to determine the active site concentrations of the MuLV and
HIV-1 RT proteins on the 23-mer T primer annealed to the 38-mer RNA
template. In this experiment, 800 M dTTP was rapidly mixed with RT
(50–75 nM active RTs) prebound onto T/P (300 nM). In the pre-steady-
state single turnover experiments that measured the dNTP concentra-
tion dependence of the purified MuLV RT protein, excess active RT (200
nM) (as determined by the burst experiments) was added to 50 nM T/P.
For studying misinsertion and mismatched primer extension fidelity,
either a matched 32P-labeled T primer (matched T primer, 5-CGCGC-
CGAATTCCCGC-3) or a mismatched 32P-labeled G/T primer (5-
CGCGCCGAATTCCCGT-3) was annealed onto the 38-mer RNA tem-
plate (see above). This generated a T/P that was identical, except that
the 3 nucleotide on the primer strand of the mismatched T/P was not
complementary to the corresponding template nucleotide, which is rep-
resentative of a mismatched T/P product formed after a misincorpora-
tion event. When examining incorrect dNTP incorporation, experiments
were carried out manually and at longer time points with higher con-
centrations of RT (400 nM). The Kd and kpol values of the RTs deter-
mined with the 16-mer T primer were similar to those determined with
the 23-mer T primer (see Table I and II). The active site concentrations
of the RT proteins with the mismatched T/P were also measured using
the same protocol as described for the matched 23-mer T-T/P (see
above). The same rapid quench protocol was used to perform the mis-
matched primer extension reactions. The pre-steady-state kinetic data
of HIV-1 RT for the misinsertion and mismatched primer extension,
which were obtained using the same protocol, have been published in
our recent study (39).
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Data Analysis—Pre-steady-state kinetic data were analyzed using
nonlinear regression. Equations were generated with the program Ka-
leidaGraph version 3.51 (Synergy Software). Data points obtained dur-
ing the burst experiment were fitted to the burst equation (36, 37).
[product]  Amp[1  exp(kobst)  ksst] (Eq. 1)
The value Amp is the amplitude of the burst, which reflects the actual
concentration of enzyme that is in active form. kobs is the observed first-
order rate constant for dNTP incorporation whereas kss is the observed
steady-state rate constant (37, 40, 47). Data from single turnover exper-
iments were fit to a single exponential equation that measures the rate of
dNTP incorporation (kobs) per given dNTP concentration ([dNTP]). These
results were then used to determine Kd, the dissociation constant for
dNTP binding to the RTT/P binary complex, and kpol, the maximum rate
of chemical catalysis/conformational change. This was done by fitting the
data to the following hyperbolic equation.
kobs  kpol[dNTP]/(Kd  [dNTP]) (Eq. 2)
From this equation, we could then identify the kinetic constants for
each RT during pre-steady-state kinetics: kpol, the maximum rate of
dNTP incorporation; and Kd, equilibrium dissociation constant for the
interaction of dNTP with the EDNA complex (37, 41).
Determination of T/P Binding Affinity (KD)—The protocol for the KD
determination has been described recently (39). Reactions to assess the
T/P concentration dependence of the RT proteins were also performed
using the Rapid Quench machine. In these experiments, active RT (50
nM) was preincubated with varying concentrations of T/P (10–700 nM).
Polymerization was initiated by addition of 800 M dTTP and allowed to
proceed at 37 °C for 250 ms. Product formation was measured and fit
into the following quadratic equation.
RT  T/P  0.5KD RTt T/P
 0.5KD RTt T/P2 4RTtT/P (Eq. 3)
The variables RT  T/P, KD, RTt, and T/P reflect productive RT-tem-
plate concentration, equilibrium dissociation constant for RT binding to
T/P, active RT concentration, and total T/P concentration, respectively.
From Eq. 3, the KD values of the MuLV RT to the aforementioned T/Ps
were determined (48).
Multiple dNTP Incorporation Assay with Matched and Mismatched
Primers—The primer extension assay was modified from a previously
described misincorporation assay (49). Briefly, a matched RNA T/P was
prepared by annealing the 38-mer RNA template (see above) to the
17-mer A primer (5-CGCGCCGAATTCCCGCT-3), and a mismatched
RNA T/P was prepared by annealing the 38-mer RNA template with the
mismatched G/T primer (see above). In addition, a mismatched DNA
T/P was prepared with a 38-mer DNA template encoding the exact
nucleotide sequence as the 38-mer RNA template annealed to a mis-
matched C/A primer (5-CGCGCCGAATTCCCGCTAA- 3). All primers
used in this assay were 32P-labeled at their 5 end (template:primer,
2.5:1). Assay mixtures (20 l) contained 10 nM T/P, the RT protein
concentrations showing the primer extension activities described in the
individual figure legends, and four dNTPs at the concentrations indi-
cated in the figure legends under the condition described in the pre-
steady-state kinetics assay described above. Reactions were incubated
at 37 °C for 5 min and terminated for analysis as described in the dNTP
assay. Concentrations of RTs (i.e. 1–4) and dNTPs (i.e. 4 and 0.04 M)
used in each primer extension experiment were described in each figure
legend. Two times more RT activities and 10-min reaction times were
used for the mismatched primer extension (2 and 4, Fig. 5), com-
pared with the matched primer extension reaction (5 min, 1 and 2,
Figs. 3 and 5). These reaction conditions allow multiple rounds of
primer extension. Products were resolved using 14% polyacrylamide-
urea gel and visualized by phosphorimager.
RESULTS
Active Site Concentrations of MuLV RT on Matched T/P—
First, we determined the active concentrations of MuLV RT
and HIV-1 RT proteins on 32P-labeled 23-mer T primer an-
nealed to a 38-mer RNA template (T-T/P). We measured prod-
uct formation when 800 M correct dTTP is mixed with RT
(50–75 nM active RT, see below) prebound onto the T/P (300 nM,
excess T/P). There is an initial burst of product formation due
to dTTP incorporation onto the prebound RTT/P complex (pre-
steady-state kinetics), which is followed by a slower and linear
phase of product formation corresponding to the steady-state
kinetics associated with multiple rounds of DNA polymeriza-
tion. By fitting these results to Eq.1, we see that MuLV RT
(Fig. 1A) and HIV-1 RT (Fig. 1B) are 50% and 32% (74.4 and
48.9 nM) active on the T-T/P, respectively. Additional data
obtained from these burst experiments include measures for
the rates of DNA polymerization during the pre-steady state
(kobs) and steady state (kss). The MuLV and HIV-1 RT pre-
steady-state rates of dTTP incorporation onto the T/P (kobs)
were 28.95 and 129.25 s1, and their rates during the steady
state were 0.13 and 0.02 s1. We also tested a second T-T/P
(16-mer T-T/P), which contains different neighboring se-
quences at the 3 end of the primers, compared with the 23-mer
T-T/P. We observed similar active site concentrations, kss and
kobs, for both RT proteins with the 16-mer T-T/P and the 23-mer
T-T/P (data not shown). Basically, like HIV-1 RT and other
DNA polymerases, MuLV RT incorporates nucleotides at a
faster rate during the pre-steady state than during the
steady state.
Pre-steady-state Kinetics of dNTP Incorporation on Matched
T/P—Next, we performed single turnover experiments (200 nM
active RT and 50 nM T/Ps) to obtain an actual measure for the
dNTP incorporation rate at different dNTP concentrations dur-
ing the pre-steady state. We first assessed the incorporation of
four different dNTPs with the four different T/Ps by MuLV and
HIV-1 RTs using single turnover experiments. By measuring
the dependence of reaction rate (kobs) on five different dNTP
concentrations (Fig. 2), we were able to measure the kinetic
parameters of Kd, which is the binding affinity of RT to the
incoming nucleotide substrate, and kpol, the maximum rate of
dNTP incorporation (conformational change and chemical ca-
talysis). As shown in Table I, the binding affinity (Kd) of MuLV
RT to dNTPs is 18.1–115.9 M, and the rate at which it incor-
porates this nucleotide (kpol) is 47.2–159.3 s
1. Interestingly,
whereas the kpol values of MuLV RT are similar to those of
HIV-1 RT on these T/Ps, MuLV RT is 6.5–121.6-fold less
efficient at binding the incoming dNTP than HIV-1 RT. To
confirm this Kd difference, we also employed the 16-mer
T-T/P (see above). In this experiment, we also observed a
40.2-fold lower Kd value for MuLV RT (44.2 M) for dTTP as
compared with HIV-1 RT (1.1 M). Both RT proteins, how-
ever, had similar kpol values of 20.0 and 21.7, respectively
(Table I). These data confirm the Kd difference between
HIV-1 RT and MuLV RT proteins, which was observed with
each of the five T/Ps with four dNTPs. Clearly, MuLV RT has
a much lower dNTP substrate binding affinity (Kd) than
HIV-1 RT, even though both RTs have similar conformational
change and catalysis capabilities (kpol), and MuLV RT has
3.5–43.8 less dNTP incorporation efficiency (kpol/Kd, Table
I) than HIV-1 RT.
[dNTP]-dependent DNA Synthesis by MuLV and HIV-1 RT
Proteins—The pre-steady-state data shown in Fig. 2 and Table
I indicate that MuLV RT has very poor dNTP binding affinity,
compared with HIV-1 RT. This kinetic difference predicts that
the dNTP binding could become a limiting step during steady
state and multiple rounds of dNTP incorporation reaction by
MuLV RT at low dNTP concentration, but not in the reactions
by HIV-1 RT. We tested this prediction using an assay allowing
multiple rounds of dNTP incorporations, a situation that better
simulates actual DNA synthesis occurring during viral repli-
cation. A 32P-labeled 17-mer primer annealed to the 38-mer
RNA template was extended at a high [dNTP] (250 M; see the
first lanes of each panel in Fig. 3) at 5 min at 37 °C, using
concentrations of MuLV and HIV-1 RTs giving 50% primer
extension. The same reaction was repeated with (different de-
creasing) dNTP concentrations (250 to 0.05 M). As shown in
Mechanism Comparison between RTs of MuLV and HIV-112192
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Fig. 3, indeed, MuLV RT failed to catalyze DNA synthesis as
dNTP concentration was decreased, whereas HIV-1 RT contin-
ued to efficiently execute DNA synthesis even at dNTP concen-
trations as low as 0.1 M. These data support the prediction
that the dNTP binding becomes a rate-limiting step during the
multiple-round and multiple nucleotide DNA synthesis by
MuLV RT at low dNTP concentrations, presumably due to the
low Kd values of MuLV RT.
Pre-steady-state Kinetics of Incorrect dNTP Incorpora-
tion—Next, we determined Kd and kpol values with incorrect
dNTPs with the matched T primer annealed to the 38-mer
RNA template. As expected, a reduction in binding affinity
for the nucleotide substrate is seen when examining the
incorrect nucleotide incorporation kinetics of these two ret-
roviral RTs, compared with their binding affinity to correct
dNTPs. As shown in Fig. 4 and summarized in Table II,
MuLV RT incorporates (kpol) incorrect dCTP and dGTP at
rates of 0.032 and 0.020 s1, respectively. These results in-
dicate that MuLV RT chemically incorporates incorrect
dNTPs at a rate similar to that seen with HIV-1 RT (Table
II). In contrast, MuLV RT is 85.4- and 13.2-fold less efficient
at binding incorrect dGTP and dCTP as compared with HIV-1
RT. The binding affinity (Kd) of the MuLV and HIV-1 RTs to
incorrect dGTP is 1178.3 and 13.8 M, respectively. Similarly,
the Kd of the MuLV and HIV-1 RTs to incorrect dCTP is
1546.5 and 117.3 M, respectively. However, the dATP mis-
incorporation was not significant enough to obtain the max-
imum primer extension, even with the highest dATP concen-
tration that could be used without nonspecific substrate
inhibition (2 mM) with this T/P.
Roberts et al. (13, 50) previously showed that MuLV RT has
a 15-fold higher fidelity than HIV-1 RT. To determine whether
FIG. 1. Active site titration of MuLV
and HIV-1 RT. Pre-steady-state and
steady-state kinetics of MuLV RT (A) and
HIV-1 RT (B) incorporating correct dTTP
onto the 32P-labeled 23-mer T primer an-
nealed to the 38-mer RNA template were
analyzed. Reactions were carried out at
the indicated times by mixing together
prebound RT (50–75 nM)T/P (300 nM)
with 800 M dTTP under rapid quench
conditions (see “Experimental Proce-
dures”). The data were fit into the burst
equation (Eq. 1) as indicated by the solid
line, which provides a measure of the ac-
tive concentration of RT (Amp), the ob-
served first-order rate constant for the
burst phase (kobs), and the first-order rate
constant for the linear phase (kss) for
MuLV and HIV RT. On the matched T/P,
the active concentration (Amp) of MuLV
RT was 74.4	 0.9 nM. Its kobs was 28.95	
5.6 s1, and its kss was 1.3  10
1	 4.3 
103 s1. On matched T/P, the active con-
centration (Amp) of HIV-1 RT was 48.9 	
4.7 nM. Its kobs was 129.25	 50.4 s
1, and
its kss was 2.2  10
2	 1.6  102 s1.
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the high fidelity nature of MuLV RT is due to its ability to
discriminate between correct and incorrect nucleotides dur-
ing the first step of mutation synthesis, we calculated the
misinsertion fidelity of this polymerase when incorporating
incorrect dGTP and dCTP. In comparison to HIV-1 RT, MuLV
RT has either a 3.6-fold higher or 4.0-fold lower misinsertion
fidelity for dGTP and dCTP, respectively (Table II). This
result suggests that a difference in misinsertion fidelity does
not explain the 15-fold higher fidelity of the MuLV RT over
HIV-1 RT. In other words, the misinsertion step may not play
a significant role in the fidelity difference between these two
RTs, which was previously implicated in the steady-state
kinetic study (20).
Kinetics Analysis of dNTP Incorporation onto Mismatched
T/P with MuLV RT—Since the misinsertion experiment de-
scribed above suggested that the misinsertion step does not
significantly contribute to the fidelity difference between
MuLV and HIV RTs, we examined the pre-steady-state kinetics
of mismatch extension (or dNTP incorporation from the mis-
matched primer), the second step of mutation synthesis. We
first examined the mismatched primer extension capability of
HIV-1 and MuLV RTs using multiple rounds of the mis-
matched primer extension reaction (Fig. 5). When the same RT
activities of HIV-1 and MuLV RTs showing 40% and 80% (1
and 2) of the 17-mer matched T/P (see ratios between fully
extended primer F and starting matched primer P in Fig. 4A;
slightly higher RT activities were used for MuLV RT) were
used, compared with HIV-1 RT, MuLV RT showed very low
capability of extending both G/T and C/A mismatched primers
annealed to the 38-mer RNA and DNA templates, respectively.
FIG. 2. Pre-steady-state kinetics of
dCTP incorporation by MuLV and
HIV-1 RTs on matched T/P. The 32P-
labeled 23-mer C primer annealed to the
38-mer RNA template (50 nM) was ex-
tended with excess RT (200 nM) for the
single-round dCTP incorporation at five
different dCTP concentrations. The kobs
value at each dCTP concentration was
plotted, and the kpol and Kd values of each
RT protein were fit into Eq. 2 as indicated
by the solid line. The data for dCTP, as
well as the other three correct dNTPs, are
summarized in Table I. A, MuLV RT in-
corporation of dCTP. B, HIV-1 RT incor-
poration of dCTP.
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These data support that the mismatch extension plays an im-
portant role in the fidelity difference between these two RTs, as
was suggested previously (20).
The protocol for the pre-steady-state kinetic analysis of mis-
match extension was described recently in our study for the
characterization of several dNTP binding mutants of HIV-1 RT
(39). We first determined the active concentration of the RT
proteins on the mismatched T/P (G/T mismatched annealed to
the 38-mer RNA template). Using the experimental conditions
and data analysis protocol described for active site titration on
a matched T/P, we see that MuLV RT is 44.9% (67.3 nM) active
on mismatched T/P (data not shown). We measured product
formation corresponding to dTTP incorporation onto mis-
matched T/P. Our results with MuLV RT are shown in Fig. 4C
and summarized in Table III. The data with HIV-1 RT have
been reported recently (39) and are shown in the Table III. The
first observation to be made is that MuLV RT is less capable of
both binding (Kd) and incorporating (kpol) dTTP onto a mis-
matched T/P in comparison with its ability to carry out polym-
erization on the matched T-T/P (Tables II and III). In this
scenario, during mismatch extension, MuLV RT incorporates
dNTP at a maximum rate of 11.6  103 s1 and has a binding
affinity of 39.4 M for the dNTP. The mismatch extension of
MuLV RT is 137.9-fold less efficient (kpol/Kd) than that of HIV-1
RT. However, because the matched primer extension (incorpo-
ration of correct dTTP) of MuLV RT is also 43.8-fold less effi-
cient than that of HIV-1 RT (Table II), the calculated mismatch
extension fidelity of MuLV RT (Table III) is 3.1-fold higher
than that of HIV-1 RT (Table III).
Interestingly, whereas the mismatched primer extension of
MuLV RT is 1552-fold less efficient than its matched primer
extension (see kpol/Kd values in incorporation of correct dTTP
with matched primer (Table II) and mismatched primers (Ta-
ble III)), it is 14–17-fold more efficient than the misincorpora-
tion efficiency. We also found that, like MuLV RT, the kpol/Kd of
HIV-1 RT for correct nucleotide incorporation on matched T/P
was greater than the kpol/Kd of mismatch extension, which, in
turn, was greater than the kpol/Kd of misincorporation. How-
ever, the efficiencies of MuLV RT in catalyzing these three
polymerization events are lower than those of HIV-1 RT. In
fact, the mismatch extension efficiency of MuLV RT (2.9 104
M1 s1; Table III) is as low as the misincorporation efficiency
of HIV RT (2.3  104 to 2.7  103 M1 s1; Table II). These
mechanistic differences between HIV-1 and MuLV RTs are
identical with the ones that we observed recently in the pre-
steady-state kinetic analyses of wild type and two HIV-1 RT
mutants, V148I and Q151N, which specifically lost their bind-
ing affinity to the incoming dNTP substrates (39).
Binding Affinity of RT Proteins to T/P—RT binding to T/P
is the mechanistic step that precedes nucleotide binding and
incorporation. In addition, due to the much lower mismatch
extension efficiency of MuLV RT (2.9  104 M1 s1),
compared with that of HIV-1 RT (0.04 M1 s1), MuLV RT is
more likely to fall off from the mismatched primer after the
misincorporation step than HIV-1 RT. Consequently, ability
to bind mismatched T/P may influence the fidelity of a po-
lymerase. To assess whether MuLV RT differs from HIV-1 RT
in its ability to perform this step in polymerization/mutation
synthesis, we measured its binding affinity (KD) to both our
matched T primer and our mismatched G/T primer annealed
onto an RNA template using the protocol described recently
(39). As shown in Table III, the KD of MuLV RT to mis-
matched primer was 203.2 nM. Compared with HIV-1 RT,
MuLV RT is 3.8-fold less able to bind mismatched T/P (Table
III), even though MuLV RT showed a similar KD to matched
primer with HIV-1 RT (data not shown) (39). These results
suggest that a diminished capacity to bind mismatched T/P
during mismatch extension can additionally contribute to the
higher fidelity of the MuLV RT in relation to wild-type HIV-1
RT.
DISCUSSION
We report here the kinetic parameters associated with DNA
polymerization and mutation synthesis by MuLV RT on an
RNA template. By concomitantly relating these findings to the
HIV-1 RT pre-steady-state kinetic results, we provide a com-
TABLE I
Pre-steady-state kinetic parameters of HIV-1 and MuLV RTs with four dNTPs
DNTPs RT
Kinetics parameters (fold differences)a
kpol Kd Kpol/Kd
s1 M M1 s1
DCTP HIV-1 37.5 	 7.5 0.334 	 0.4 112.5MuLV 47.2 	 8.1 (1.3) 18.1 	 9.4 (54.2) 2.6 (43.3)
DATP HIV-1 33.7 	 0.6 0.610 	 0.5 55.3MuLV 159.2 	 4.7 (4.7) 74.2 	 1.2 (121.6) 2.1 (26.3)
DGTP HIV-1 39.4 	 5.6 3.9 	 0.04 10.2MuLV 72.2 	 3.8 (1.8) 25.2 	 8.3 (6.5) 2.9 (3.5)
DTTP HIV-1 36.6 	 7.5 2.5 	 1.4 14.6MuLV 159.3 	 14.9 (4.4) 115.9 	 9.3 (46.4) 1.4 (10.4)
DTTPb HIV-1
c 21.7 	 0.7 1.1 	 0.1 19.7
MuLV 20.0 	 0.6 (1.1) 44.2 	 4.0 (40.2) 0.45 (43.8)
a Fold differences of MuLV RT relative to HIV-1 RT.
b dTTP incorporation with the 16-mer matched T primer.
c Data published previously (39).
FIG. 3. Primer extension by HIV-1 and MuLV RTs at different
dNTP concentrations. 32P-labeled 17-mer primer (S) annealed to the
38-mer RNA template was incubated with HIV-1 (A) and MuLV (B) RTs
showing 50% of primer extension (F) at 37 °C for 5 min with 250 M
dNTP (the highest dNTP concentration). The same reaction was re-
peated with seven decreasing dNTP concentrations (25, 5, 1, 0.5, 0.25,
0.1, and 0.05 M). The reactions were analyzed with 14% denaturing
polyacrylamide gels.
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prehensive mechanistic comparison of the HIV-1 and MuLV
RTs. Firstly, we examined the kinetics for the incorporation of
four different dNTPs (correct) by MuLV and HIV-1 RTs. In this
experiment, we observed that whereas the kpol values of HIV-1
and MuLV RTs for dNTPs are very similar, MuLV RT binds
nucleotide substrates with 6.5–121.6-fold lower affinity than
HIV-1 RT. We reasoned that the lower binding affinity of
MuLV RT to correct dNTPs may contribute to its higher steady-
state Km values compared with HIV-1 RT (7–11). As shown in
our multiple nucleotide incorporation reaction (Fig. 3), MuLV
FIG. 4. MuLV RT pre-steady-state
kinetics on misinsertion and mis-
match extension. Assessment of nucle-
otide incorporation on matched T/P repre-
sents events associated with the first step
of mutation synthesis, misinsertion. The
concentration dependence of MuLV RT
for incorrect dCTP (A) and incorrect dGTP
(B) was determined. We measured kobs for
each nucleotide at varying concentrations
and fit our results into Eq. 2 (indicated by
the solid line) to calculate the correspond-
ing values of kpol and Kd. The kpol and Kd
were 0.032 	 0.002 s1 and 1546.5 	
176.7 M for incorrect dCTP and 0.020 	
0.002 s1 and 1178.3 	 169.2 M for in-
correct dGTP. These kinetic data are
summarized in Table II. C, dTTP incorpo-
ration onto a mismatched T/P represents
the second step of mutation synthesis,
mismatch extension. The concentration
dependence of MuLV RT for correct dTTP
was determined. We measured kobs for
dTTP at varying concentrations and fit
our results into Eq. 2 (indicated by the
solid line) to calculate the corresponding
values of kpol and Kd. On mismatched T/P,
the kpol and Kd of MuLV RT for correct
dTTP was 11.6  103	 0.1  103 s1
and 39.4 	 2.3 M, respectively. These
data are summarized in Table III.
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RT clearly displayed a great reduction of the DNA synthesis at
low dNTP concentrations. It is possible that, when the dNTP
availability is low, the dNTP binding step of MuLV RT becomes
rate-limiting, which reduces its capability of executing multiple
nucleotide incorporations that normally occur during viral
DNA synthesis. We recently demonstrated that MuLV RT
also shows lower dNTP incorporation efficiency than HIV-1
RT under a single round of processive DNA synthesis at low
dNTP concentrations (i.e. 40 nM) (6). In contrast, due to the
tight dNTP binding affinity of HIV-1 RT, this RT protein is
still able to retain synthesis activity, even at low dNTP
concentrations. This is also consistent with the low steady-
state Km values of HIV-1 RT, compared with those of MuLV
RT (6–8). The same multiple nucleotide incorporation differ-
ence seen between HIV-1 and MuLV RTs (Fig. 3) was also
observed between the wild type and two dNTP binding mu-
tants (Q151N and V148I) of HIV-1 RT (6). Models suggested
that these two mutations disrupt the interaction between the
RT active site and the 3 OH of the incoming dNTP substrate,
resulting in an increase of the Kd values without affecting the
kpol values (39). Basically, these two dNTP binding HIV-1 RT
mutant proteins kinetically mimic MuLV RT in DNA
polymerization.
Here, using a series of virological and cellular aspects related
with these two different retroviruses, MuLV and HIV-1, we
envision possible significances of the dNTP binding difference
between these two RTs. Firstly, HIV-1, which is a lentivirus,
uniquely infects not only dividing cells (i.e. activated CD4 T
cells) but also nondividing/terminally differentiated cells (ma-
ture macrophages), whereas MuLV, an oncoretrovirus, re-
quires proliferating cells (4). Macrophage infection, which is
observed in the early asymptomatic phase of HIV-1 infection, is
a hallmark phenotype of HIV-1 pathogenesis. Secondly, numer-
ous studies have reported that nondividing cells have much
lower cellular dNTP concentrations than dividing cells (5).
Using a novel dNTP assay, we recently demonstrated that the
dNTP concentration of human mature macrophages is 40
nM, which is 100-fold lower than that of activated CD4 T
cells (2–5 M) (6). More importantly, the steady-state Km
values of HIV-1 and MuLV RTs lie near the cellular dNTP
concentrations found in macrophages and activated T cells,
respectively. Considering all these findings, we can speculate
that the tight binding of the HIV-1 active site to the incoming
dNTP substrate may contribute to the unique capability of
HIV-1 to infect nondividing cells containing low cellular
dNTP concentrations. Conversely, the active site of MuLV RT
may have adapted to the high dNTP concentration environ-
ments found in the dividing cells that MuLV normally infects.
This possibility is further supported by our recent observa-
tion that HIV-1 variants harboring RT mutants (V148I and
Q151N), which kinetically mimic MuLV RT due to their re-
duced dNTP binding affinity, failed to infect macrophages
even though these mutant viruses normally infect dividing
cells (i.e. activated CD4 T cells and transformed cell lines)
(6).
Pre-steady-state kinetic study on the M184V 3TC-resistant
HIV-1 RT mutant demonstrated that the M184V mutation,
which lies near the active site containing the conserved YXDD
sequence, slightly increases Kd values (2–6-fold) to dCTP (41),
which may explain low infectivity in cells with low dNTP con-
tents (51, 52). This mutant RT also has reduced processivity
(53), compared with wild-type HIV-1 RT, which could be re-
sponsible for lower infectivity of this mutant virus in primary
cells (53, 54). Pre-steady-state kinetic analysis on M184I,
which only transiently appears during the 3TC treatment, has
not been reported. Interestingly, unlike M184V, M184I has
noticeable decreases in the DNA synthesis at low dNTP con-
centrations,2 supporting that M184I RT, which has a longer
-branched side chain than the Val mutation, may also affect
the binding of dNTP to the active site as observed in Q151N
and V148I. Our recent pre-steady-state kinetic analysis
showed that RT of simian immunodeficiency virus, another
lentivirus infecting nondividing cells, also has lower Kd values,
like HIV-1 RT (49). Additionally, we observed that RT of feline
leukemia virus (an oncoretrovirus) has higher Km values than
RT of feline immunodeficiency virus (a lentivirus).2 These com-
bined findings support the idea that the dNTP utilization effi-
2 M. Skasko, K. K. Weiss, H. M. Reynolds, V. Jamburuthugoda,
K. Lee, and B. Kim, unpublished observations.
TABLE II
Pre-steady-state kinetic parameters of HIV-1 and MuLV RTs for misincorporation
dNTP RT
Kinetic parameters (fold differences)a
kpol Kd kpol/Kd Misinsertion fidelity
b
s1 M M1 s1
DTTP (correct) HIV-1
c 21.7 	 0.7 1.1 	 0.1 19.7
MuLV 20.0 	 0.6 (1.1) 44.2 	 4.0 (40.2) 0.45 (43.8)
DGTP (incorrect) HIV-1
c 0.037 	 0.001 13.8 	 2.2 2.7  103 7296.3
MuLV 0.020 	 0.002 (1.9) 1178.3 	 169.2 (85.4) 1.7  105 (158.8) 26470.6 (3.6)
DCTP (incorrect) HIV-1
c 0.027 	 0.001 117.3 	 7.3 2.3  104 85652.2
MuLV 0.032 	 0.002 (1.2) 1546.5 	 176.7 (13.2) 2.1  105 (10.9) 21428.6 (0.25)
a Fold differences of MuLV RT relative to HIV-1 RT.
b (kpol/Kd)correct/(kpol/Kd)incorrect.
c Data published previously (39).
FIG. 5.Mismatch extension capability of MuLV and HIV-1 RTs.
A, the 32P-labeled matched primer (P) annealed to the 38-mer RNA
template was extended by two different concentrations of HIV-1 and
MuLV RTs showing 35% (1) and 70% (2) of the primer extension
(F) at 37 °C for 5 min with 250 M dNTP. B, the primer extension
reactions were repeated with either G/T (left panel) or C/A (right panel)
mismatched primer (MP) annealed to the 38-mer RNA or DNA tem-
plate, respectively, under the same conditions used in the matched T/P
reactions (A), except for twice more RT activity (2 and 4). The
reactions were analyzed with 15% denaturing polyacrylamide gels.
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ciency and dNTP binding affinity of RTs contribute to the host
cell specificity of retroviruses. The generality of this idea needs
to be further explored by analyzing more RT proteins isolated
from different retroviruses. Furthermore, note that, in order to
complete viral replication in nondividing cells, HIV-1 also re-
quires a viral accessory protein, viral protein R (Vpr), which
enables the pre-integration complex containing the synthesized
proviral DNA to enter the nucleus through the nuclear mem-
brane that remains intact in nondividing cells (55, 56). In
contrast, other retroviruses, which infect dividing cells, do not
require this transport mechanism because the pre-integration
complex of these viruses can access chromosomes during mito-
sis where the nuclear membrane barrier disintegrates.
Both MuLV and HIV-1 RTs displayed similar characteristics
in dNTP binding and catalysis during misinsertion events.
Whereas the rate (kpol) at which MuLV RT incorporates incor-
rect dNTPs is comparable with that observed with HIV-1 RT,
the binding affinity (Kd) of MuLV RT for incorrect dNTPs is
13.2–85.4-fold lower than that of HIV-1 RT. However, because
MuLV RT has diminished binding affinity (Kd) for both correct
and incorrect dNTPs, there is a simultaneous reduction in its
efficiency (kpol/Kd) of correct and incorrect dNTP incorporation.
The net effect is that HIV-1 and MuLV RTs have similar
misinsertion fidelities (Table II).
The differences between these two RTs became apparent
when we measured the kinetics of mismatch extension for
MuLV RT. When incorporating correct dNTP onto a mis-
matched T/P, this polymerase is altered in its ability to bind
(Kd) and catalyze the incorporation (kpol) of the nucleotide
substrate, even though the primary difference between these
RTs is the rate (kpol) at which they carry out mismatch exten-
sion. HIV-1 RT incorporates dTTP onto a mismatched T/P at a
maximum rate of 0.45 s1, which is 43.8-fold faster than the
rate of mismatch extension observed with the MuLV RT. The
changes in dNTP binding and chemical catalysis translate into
a 137.9-fold reduction in mismatch extension efficiency (kpol/
Kd) for MuLV RT in comparison with HIV-1 RT. The fact that
MuLV RT is so inefficient at carrying out mismatch extension
supports the likelihood that the polymerase stalls and falls off
the mismatched T/P substrate. In this scenario, it is necessary
to assess the capability of MuLV RT to rebind the mismatched
T/P. We show that MuLV RT has a 3.8-fold lower binding
affinity for mismatched T/P (KD) than HIV-1 RT. This result
indicates that the overall higher fidelity of MuLV RT relative to
HIV-1 RT is due to multiple effects of 1) a 3.1-fold higher
mismatch extension fidelity and 2) a 3.8-fold reduced ability to
rebind mismatched T/P when RT disassociates from the T/P
substrate. Due to a 137.9-fold less efficient mismatch extension
and poor binding to mismatched T/P, MuLV RT may more
likely release from the mismatched T/P after misinsertion. This
could create an additional mechanistic barrier that could slow
down the mismatch extension step as observed in Fig. 5 and
overall mutation synthesis by MuLV RT. In contrast, due to the
tighter binding affinity to the mismatched primer and highly
efficient capability to extend the mismatched primer, relative
to MuLV RT, HIV-1 RT may be able to continue the mismatch
extension without falling off from the mismatched T/P, which
can lead to high success in the completion of the mutation
synthesis by HIV-1 RT.
Using fingerprinting and sequencing analysis of proviral
DNA, Monk et al. (57) reported that MuLV infection of a clonal
cell line yielded a mutation rate of 2  105 bases per replica-
tion cycle. Using the cell-free M13 lacZ forward mutation
assay, Roberts et al. (50) reported that the MuLV RT had an
error rate of 1/30,000, which can account for the estimated in
vivo MuLV mutation rate published in the aforementioned
study. Nevertheless, Roberts et al. (50) did report that the error
rate of MuLV RT is15-fold higher than that of HIV-1 RT, and
our findings suggest that the mechanism responsible for this
fidelity difference is their differing abilities to complete the
process of mismatch extension. The idea that mismatch exten-
sion plays an important role in determining the overall fidelity
of retroviral RTs was established in 1989 when Perrino et al.
(58) reported that HIV-1 RT is 50-fold more efficient than DNA
polymerase  at synthesizing DNA from a mismatched T/P.
This property was characterized in a more quantitative man-
ner when Bakhanashvili and Hizi (20, 59) measured the
steady-state kinetics of mismatch extension for both HIV-1 and
MuLV RTs. When they measured the mismatch extension ca-
pabilities of these two polymerases with three different mis-
matched T/Ps, the authors reported that the relative mismatch
extension frequencies of MuLV RT were, on average, 2–3-fold
lower than those seen with HIV-1 RT.
The fact that HIV-1 RT is very efficient (kpol/Kd) at carrying
out mismatch extension emphasizes the underlying differences
between HIV-1 RT and other retroviral polymerases. The viral
polymerase of HIV-1 must have evolved so that its active site is
more permissive to introducing mutations into the viral ge-
nome. Interestingly, our laboratory has recently identified a
molecular interaction within the HIV-1 RT active site that
influences how efficiently this polymerase is able to complete
the second step of mutation synthesis (39, 45). The Gln151
residue is part of the highly conserved LPQG motif found in all
retroviral RTs. Previous studies have shown that the interac-
tion between this residue and the dNTP substrate is a deter-
minant for HIV-1 RT fidelity (26, 45, 46, 60, 61). When we
performed a comprehensive analysis on the Q151N mutant RT
in order to assess its mutation synthesis capabilities, we dis-
covered that alterations in the Gln151 residue reduced the
efficiency with which HIV-1 RT incorporated correct dNTP into
both matched and mismatched T/Ps (39). More specifically,
Q151N has a higher Kd value and a lower kpol value than
wild-type HIV-1 RT during mismatch extension, as observed in
this study with MuLV RT. In addition, whereas Q151N has a
reduced Kd (but not kpol) value for both correct and incorrect
dNTPs compared with wild-type HIV-1 RT, Q151N does not
alter the binding affinity to matched or mismatched primers.
This finding suggested that the interactions between Gln151
TABLE III
Pre-steady state kinetic parameters of dTTP incorporation by HIV-1 and MuLV RTs and
binding affinity of MuLV and HIV-1 RTs for mismatched T/P
RT kpol Kd kpol/Kd
Mismatch extension
fidelitya
Binding affinity (Kd)
to mismatched T/Pb
s1 M M1 s1 nM
HIV-1c 0.5 	 5.6  103 14.1 	 0.6 0.04 493.5 53.8 	 2.8
MuLV 11.6  103 	 0.1  103 (43.1)d 39.4 	 2.3 (2.8)d 2.9  104 (137.9)d 1552.7 (3.1)d 203.2 	 7.6 (3.8)
a (kpol/Kd)matched/(kpol/Kd)mismatched.
b Kd values were obtained using Eq. 3 as described previously (48).
c Data published previously (39).
d Fold difference in fidelity relative to wild-type HIV-1 RT.
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and the dNTP substrate within the HIV-1 RT active site appear
to influence how efficiently this polymerase is able to complete
mismatch extension. Interestingly, however, these mechanistic
differences between wild-type and Q151N HIV-1 RT proteins
are very similar to those observed between HIV-1 and MuLV
RTs. This indicates that the active site of the Q151N dNTP
binding mutant HIV-1 RT kinetically functions more like the
active site of MuLV RT. A similar interaction may occur within
the MuLV RT active site, given that it encodes an equivalent
residue, Gln190. Biochemical data showing that alterations
(Q190N) in this residue can increase the fidelity of the MuLV
RT suggest that this residue has the same functional role in
both the HIV-1 and MuLV RTs (28, 30). However, given the
dramatic difference in the mismatch extension fidelities be-
tween the wild-type proteins of these two RTs, it is plausible
that there exist interactions (in addition to those with Gln151)
between HIV-1 RT and the mismatch extension intermediates
that are not present in the MuLV RT.
In addition to Q151N and V148I, the fidelity of the M184V
HIV-1 RT, which renders 3TC resistance, has been charac-
terized by pre-steady-state kinetic analysis (41). The M184V
HIV-1 RT, which showed an 2-fold increase fidelity in M13
lacZ forward mutation assay (62), showed a maximum 2.4
higher fidelity than wild-type RT in the kinetic analysis.
Interestingly, the Kd increase contributes to the high fidelity
nature of M184V. In addition, M184V HIV-1 RT also showed
reduced mismatch primer extension capability (63). M184I
HIV-1 RT showed slightly higher fidelity than M184V (62).
However, the pre-steady-state kinetic analysis has not been
reported. A number of other HIV-1 RT mutations altering
enzyme fidelity were isolated: D76V (64), R78A (65), E89G
(63), and the residues in the minor groove binding track (66,
67). Structural models on D76V, R78A, and E89G suggested
that these mutations may affect the RT interaction with
template, whereas the minor groove binding track residues
interact with the minor groove of the T/P, where the transi-
tion from A to B DNA and bending occur. Our pre-steady-
state kinetic study shows that D76V and R78A do not show
any altered Kd and kpol values,
2 which is consistent with the
previous report that these mutations mainly affect RT bind-
ing to the single-stranded part of the primer (64, 65). Muta-
tions in the minor groove binding track region (i.e. Gly266 and
Trp266) mainly affect replication frameshift mutation and
processivity through altering the RT interaction with the
minor groove of the double-stranded T/P. Basically, these
studies with the RT mutants with altered fidelity suggest
that the RT interaction with substrates, dNTP and T/P, is a
key determinant for RT fidelity.
In summary, this is the first time that a comprehensive
pre-steady-state kinetic analysis of dNTP incorporation and
mutation synthesis by MuLV RT has been reported. The mech-
anistic analysis of HIV-1 and MuLV RTs clearly sheds lights on
the functional and evolutionary relatedness between the dNTP
interactions within the RT active site and the virological char-
acteristics of retroviruses such as cell type specificity and
genomic mutagenesis.
Acknowledgments—We are thankful to Drs. Robert A. Bambara,
Vandana Purohit, and Mini Balakrishnan for thoughtful discussion.
REFERENCES
1. Fields, B. N., Knipe, D. M., and Howley, P. M. (1996) Fields Virology, 3rd ed.,
Lippincott-Raven Publishers, New York
2. De Clercq, E. (1992) AIDS Res. Hum. Retroviruses 8, 119–134
3. Lewis, P., Hensel, M., and Emerman, M. (1992) EMBO J. 11, 3053–3058
4. Lewis, P. F., and Emerman, M. (1994) J. Virol. 68, 510–516
5. Traut, T. W. (1994) Mol. Cell. Biochem. 140, 1–22
6. Diamond, T. L., Roshal, M., Jamburuthugoda, V. K., Reynolds, H. M., Mer-
riam, A. R., Lee, K. Y., Balakrishnan, M., Bambara, R. A., Planelles, V.,
Dewhurst, S., and Kim, B. (2004) J. Biol. Chem. 279, 51545–51553.
7. Chowdhury, K., Kaushik, N., Pandey, V. N., and Modak, M. J. (1996) Biochem-
istry 35, 16610–16620
8. Furge, L. L., and Guengerich, F. P. (1997) Biochemistry 36, 6475–6487
9. Shi, Q., Singh, K., Srivastava, A., Kaushik, N., and Modak, M. J. (2002)
Biochemistry 41, 14831–14842
10. Ueno, T., Shirasaka, T., and Mitsuya, H. (1995) J. Biol. Chem. 270,
23605–23611
11. Woodside, A. M., and Guengerich, F. P. (2002) Biochemistry 41, 1027–1038
12. Diamond, T. L., Kimata, J., and Kim, B. (2001) J. Biol. Chem. 276,
23624–23631
13. Roberts, J. D., Preston, B. D., Johnston, L. A., Soni, A., Loeb, L. A., and
Kunkel, T. A. (1989) Mol. Cell. Biol. 9, 469–476
14. Bebenek, K., Abbotts, J., Roberts, J. D., Wilson, S. H., and Kunkel, T. A. (1989)
J. Biol. Chem. 264, 16948–16956
15. Preston, B. D., Poiesz, B. J., and Loeb, L. A. (1988) Science 242, 1168–1171
16. Battula, N., and Loeb, L. A. (1974) J. Biol. Chem. 249, 4086–4093
17. Perach, M., and Hizi, A. (1999) Virology 259, 176–189
18. Avidan, O., Meer, M. E., Oz, I., and Hizi, A. (2002) Eur. J. Biochem. 269,
859–867
19. Bakhanashvili, M., and Hizi, A. (1993) Biochemistry 32, 7559–7567
20. Bakhanashvili, M., and Hizi, A. (1992) Biochemistry 31, 9393–9398
21. O’Neil, P. K., Sun, G., Yu, H., Ron, Y., Dougherty, J. P., and Preston, B. D.
(2002) J. Biol. Chem. 277, 38053–38061
22. Mansky, L. M., Le Rouzic, E., Benichou, S., and Gajary, L. C. (2003) J. Virol.
77, 2071–2080
23. Mansky, L. M. (2000) J. Virol. 74, 9525–9531
24. Hsiou, Y., Ding, J., Das, K., Clark, A. D., Jr., Hughes, S. H., and Arnold, E.
(1996) Structure (Lond.) 4, 853–860
25. Georgiadis, M. M., Jessen, S. M., Ogata, C. M., Telesnitsky, A., Goff, S. P., and
Hendrickson, W. A. (1995) Structure (Lond.) 3, 879–892
26. Harris, D., Kaushik, N., Pandey, P. K., Yadav, P. N., and Pandey, V. N. (1998)
J. Biol. Chem. 273, 33624–33634
27. Kaushik, N., Singh, K., Alluru, I., and Modak, M. J. (1999) Biochemistry 38,
2617–2627
28. Singh, K., Kaushik, N., Jin, J., Madhusudanan, M., and Modak, M. J. (2000)
Protein Eng. 13, 635–643
29. Kaushik, N., Talele, T. T., Pandey, P. K., Harris, D., Yadav, P. N., and Pandey,
V. N. (2000) Biochemistry 39, 2912–2920
30. Jin, X., Bauer, D. E., Tuttleton, S. E., Lewin, S., Gettie, A., Blanchard, J.,
Irwin, C. E., Safrit, J. T., Mittler, J., Weinberger, L., Kostrikis, L. G., Zhang,
L., Perelson, A. S., and Ho, D. D. (1999) J. Exp. Med. 189, 991–998
31. Wainberg, M. A., Hsu, M., Gu, Z., Borkow, G., and Parniak, M. A. (1996) AIDS
10, S3–S10
32. Faraj, A., Agrofoglio, L. A., Wakefield, J. K., McPherson, S., Morrow, C. D.,
Gosselin, G., Mathe, C., Imbach, J. L., Schinazi, R. F., and Sommadossi,
J. P. (1994) Antimicrob. Agents Chemother. 38, 2300–2305
33. Wainberg, M. A., Drosopoulos, W. C., Salomon, H., Hsu, M., Borkow, G.,
Parniak, M., Gu, Z., Song, Q., Manne, J., Islam, S., Castriota, G., and
Prasad, V. R. (1996) Science 271, 1282–1285
34. Drosopoulos, W. C., and Prasad, V. R. (1998) J. Virol. 72, 4224–4230
35. Rezende, L. F., Curr, K., Ueno, T., Mitsuya, H., and Prasad, V. R. (1998)
J. Virol. 72, 2890–2895
36. Johnson, K. A. (1993) Annu. Rev. Biochem. 62, 685–713
37. Johnson, K. A. (1995) Methods Enzymol. 249, 38–61
38. Zinnen, S., Hsieh, J. C., and Modrich, P. (1994) J. Biol. Chem. 269,
24195–24202
39. Weiss, K. K., Chen, R., Skasko, M., Reynolds, H. M., Lee, K., Bambara, R. A.,
Mansky, L. M., and Kim, B. (2004) Biochemistry 43, 4490–4500
40. Kati, W. M., Johnson, K. A., Jerva, L. F., and Anderson, K. S. (1992) J. Biol.
Chem. 267, 25988–25997
41. Feng, J. Y., and Anderson, K. S. (1999) Biochemistry 38, 9440–9448
42. Carroll, S. S., Cowart, M., and Benkovic, S. J. (1991) Biochemistry 30,
804–813
43. Malboeuf, C. M., Isaacs, S. J., Tran, N. H., and Kim, B. (2001) BioTechniques
30, 1074–1078, 1080, 1082, passim
44. Kim, B. (1997) Methods (Orlando) 12, 318–324
45. Weiss, K. K., Isaacs, S. J., Tran, N. H., Adman, E. T., and Kim, B. (2000)
Biochemistry 39, 10684–10694
46. Weiss, K. K., Bambara, R. A., and Kim, B. (2002) J. Biol. Chem. 277,
22662–22669
47. Kerr, S. G., and Anderson, K. S. (1997) Biochemistry 36, 14064–14070
48. Suo, Z., and Johnson, K. A. (1997) Biochemistry 36, 12459–12467
49. Diamond, T. L., Souroullas, G., Weiss, K. K., Lee, K. Y., Bambara, R. A.,
Dewhurst, S., and Kim, B. (2003) J. Biol. Chem. 278, 29913–29924
50. Roberts, J. D., Bebenek, K., and Kunkel, T. A. (1988) Science 242, 1171–1173
51. Back, N. K., Nijhuis, M., Keulen, W., Boucher, C. A., Oude Essink, B. O., van
Kuilenburg, A. B., van Gennip, A. H., and Berkhout, B. (1996) EMBO J. 15,
4040–4049
52. Miller, M. D., Anton, K. E., Mulato, A. S., Lamy, P. D., and Cherrington, J. M.
(1999) J. Infect. Dis. 179, 92–100
53. Harris, D., Yadav, P. N., and Pandey, V. N. (1998) Biochemistry 37, 9630–9640
54. Naeger, L. K., Margot, N. A., and Miller, M. D. (2001) Antivir. Ther. 6,
115–126
55. de Noronha, C. M., Sherman, M. P., Lin, H. W., Cavrois, M. V., Moir, R. D.,
Goldman, R. D., and Greene, W. C. (2001) Science 294, 1105–1108
56. Sherman, M. P., de Noronha, C. M., Eckstein, L. A., Hataye, J., Mundt, P.,
Williams, S. A., Neidleman, J. A., Goldsmith, M. A., and Greene, W. C.
(2003) J. Virol. 77, 7582–7589
57. Monk, R. J., Malik, F. G., Stokesberry, D., and Evans, L. H. (1992) J. Virol. 66,
3683–3689
58. Perrino, F. W., Preston, B. D., Sandell, L. L., and Loeb, L. A. (1989) Proc. Natl.
Acad. Sci. U. S. A. 86, 8343–8347
59. Bakhanashvili, M., and Hizi, A. (1993) FEBS Lett. 319, 201–205
Mechanism Comparison between RTs of MuLV and HIV-1 12199
 by guest on A
ugust 22, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
60. Kaushik, N., Harris, D., Rege, N., Modak, M. J., Yadav, P. N., and Pandey,
V. N. (1997) Biochemistry 36, 14430–14438
61. Sarafianos, S. G., Pandey, V. N., Kaushik, N., and Modak, M. J. (1995)
Biochemistry 34, 7207–7216
62. Rezende, L. F., Drosopoulos, W. C., and Prasad, V. R. (1998)Nucleic Acids Res.
26, 3066–3072
63. Hamburgh, M. E., Drosopoulos, W. C., and Prasad, V. R. (1998) Nucleic Acids
Res. 26, 4389–4394
64. Kim, B., Hathaway, T. R., and Loeb, L. A. (1998) Biochemistry 37,
5831–5839
65. Kim, B., Ayran, J. C., Sagar, S. G., Adman, E. T., Fuller, S. M., Tran, N. H., and
Horrigan, J. (1999) J. Biol. Chem. 274, 27666–27673
66. Beard, W. A., Bebenek, K., Darden, T. A., Li, L., Prasad, R., Kunkel, T. A., and
Wilson, S. H. (1998) J. Biol. Chem. 273, 30435–30442
67. Latham, G. J., Forgacs, E., Beard, W. A., Prasad, R., Bebenek, K., Kunkel,
T. A., Wilson, S. H., and Lloyd, R. S. (2000) J. Biol. Chem. 275, 15025–15033
Mechanism Comparison between RTs of MuLV and HIV-112200
 by guest on A
ugust 22, 2019
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
